Absence of the Factor V Leiden mutation and genetic risk for CTEPH

Similar documents
Thrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI

Choosing Wisely: If, When, What, and Who to Test for Thrombophilia

Duration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016

Citation for published version (APA): van Vlijmen, E. F. W. (2016). The pill and thrombosis. [Groningen]: Rijksuniversiteit Groningen.

New Guidance in AT10 Clive Kearon, MD, PhD,

Thrombophilia. Stephan Moll, MD Medicine, Heme-Coag UNC Chapel Hill, NC. GASCO Atlanta Sept 8 th, Disclosures. Conflicts of interest: NONE

Scott M. Stevens, MD. Co-Director, Thrombosis Clinic. Associate Professor of Clinical Medicine

Duration of anticoagulation

THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO

Acute and long-term treatment of PE. Cecilia Becattini University of Perugia

Real life management of CTEPH: patient case

Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR

PULMONARY EMBOLISM/VTE CARE PROCESS MODEL

Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수

Direct oral anticoagulants to prevent VTE recurrence: full or reduced dosage? MA Sevestre CHU Amiens

UC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE

Cover Page. The handle holds various files of this Leiden University dissertation

Μακροχρόνια παρακολούθηση ασθενών με πνευμονική εμβολή

Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium

Inherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD

Cryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do?

VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?

VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT

PE service. 65 years old lady. What would you do next? Risk stratification. What would you do next? Regional College Lecture PE Management

Top Ten Reasons For Failure To Prevent Postoperative Thrombosis

Learning Objectives. Outline. CTEPH: Practice Guidelines. History. 36 y/o Man with Chest Pain and Dyspnea

University of Groningen

Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life

ACTIVITY DESCRIPTION Target Audience Learning Objectives

Thrombophilia: To test or not to test

Duration of Therapy for Venous Thromboembolism

A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden

Controversies in Venous Thromboembolism

Changing the Ambulatory Training Paradigm: The Design and Implementation of an Outpatient Pulmonology Fellowship Curriculum

Clinical Guideline for Anticoagulation in VTE

venous thromboembolism

How to prevent thrombotic diseases? Sergio Fusco, MD

Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018

Understanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal

Mabel Labrada, MD Miami VA Medical Center

DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center

Thromboembolism and cancer: New practices. Marc Carrier

DOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University

DOACs in SPECIAL POPULATIONS

Acute Pulmonary Embolism and Deep Vein Thrombosis. Barbara LeVarge MD Beth Israel Deaconess Medical Center Pulmonary Hypertension Center COPYRIGHT

Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism

RISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM. David Jiménez, MD, PhD, FCCP Ramón y Cajal Hospital, IRYCIS Madrid, Spain

Approach to Thrombosis

Insights from whole genome sequencing of a family with Venous Thromboembolism

Updates in venous thromboembolism. Cecilia Becattini University of Perugia

Anticoagulation Update: VTE Guidelines update, DOACs, procedural warfarin interruption, and icentra (whew!)

Underuse of risk assessment and overuse of CTPA in patients with suspected pulmonary thromboembolism

Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program

PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM

Original Policy Date

WGA meeting Management and follow-up VTE in clinical pratice Dr Borgoens CHR Citadelle Liège

Venous Thrombosis in Asia

Guidance for the evaluation and treatment of hereditary and acquired thrombophilia

Updates in Diagnosis & Management of VTE

Vascular Protection: Preventing Thrombotic Complications of VTE and PAD

Epidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005

Perioperative VTE prophylaxis (ACCP 9 th edition Guidelines) Gamal Marey SUNY Downstate Medical Center 10/16/2014

The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study

VENOUS THROMBOEMBOLISM

New Developments in VTE Treatment

Updates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017

Evaluating the Post Pulmonary Embolism Patient: What You Need to Know

Anticoagulation Update: DOACs, VTE Guidelines, Bridging and icentra

CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow

Hemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures

With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis

Results from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY

UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS

After a first episode of acute venous thromboembolism

Risk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD

Venous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD

Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden

Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital Foundation Trust

THROMBOPHILIA SCREENING

Thrombophilia testing: who is it good for? F.R. Rosendaal, Leiden

Acute and long-term treatment of VTE. Cecilia Becattini University of Perugia

Prevention and treatment of venous thromboembolic disease

Chapter. A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families

Post-Thrombotic Syndrome Prevention and Management. Dr. Ashwini Bennett

Highlights. Saman Salim 1 Moncef Zarrouk 1,3 Johan Elf 1,3 Anders Gottsäter 1,3 Signy Sveinsdottir 2 Peter Svensson 2,4 Stefan Acosta 1,3

PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT

DECLARATION OF CONFLICT OF INTEREST

Massive and Submassive Pulmonary Embolism: 2017 Update and Future Directions

Chapter 8. F.A. Klok, K.W. van Kralingen, A.P.J. van Dijk, F.H. Heyning, H.W. Vliegen and M.V. Huisman. Haematologica 2009; in press

Pharmacy Prior Authorization

Anticoagulation: Novel Agents

DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)

Chapter 1. Introduction

Pulmonary Thromboembolism

Molecular mechanisms & clinical consequences. of prothrombin mutations. A.J. Hauer

Anticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita

ASH 2011: Clinically Relevant Highlights Regarding Venous Thromboembolism and Anticoagulation

Transcription:

Absence of the Factor V Leiden mutation and genetic risk for CTEPH Mark W. Dodson, MD, PhD Assistant Professor, Pulmonary/Critical Care Intermountain Medical Center Murray, Utah

A paradox in our current understanding of genetic risk for CTEPH Unprovoked PE is a major risk factor for CTEPH. 1 Patients with unprovoked PE are twice as likely to carry the Factor V Leiden mutation. 2 But the frequency of the Factor V Leiden mutation is no different in patients with CTEPH than in the general population. 3,4,5 1. Klok, et al. J Thromb Haemost, 2015. 2. Couturaud, et al. Blood, 2014. 3. Lang, et al. Thromb Haemost, 1996. 4. Wolf, et al. Eur Resp J, 2000. 5. Suntharalingam, et al. Eur Resp J, 2008.

A paradox in our current understanding of genetic risk for CTEPH Unprovoked VTE is associated: increased risk of recurrent VTE 1 increased occurrence of VTE in family members 2 Thus, unprovoked VTE is a marker of increased genetic risk for VTE. Does the high frequency of unprovoked VTE in patients with CTEPH reflect increased genetic risk for VTE that is not explained by the Factor V Leiden mutation? 1. Kearon, et al. Chest, 2012. 2. Couturaud, et al. Blood, 2014.

Methods Two cohorts: 1. Patients with CTEPH 2. Patients with VTE (PE or proximal LE DVT) without signs or symptoms of CTEPH who are matched to the CTEPH cohort on: Age at first diagnosed VTE event Proportion with unprovoked VTE Simultaneously compare the frequency of Factor V Leiden positivity and family history of VTE.

Family history as a marker of genetic risk for VTE Known inherited thrombophilias are estimated to explain only a small percentage (~5%) of the genetic risk for VTE. 1 Relative risk of VTE in person with VTE in one first degree family member is ~2.5 2,3,4. Relative risk increases if: VTE in family member is unprovoked. 5 Younger age at time of VTE in family member. 4,5 Multiple affected first degree family members. 3,4,5 1. Morange, et al. Thromb Haemost, 2015. 2. Noboa et al. Thromb Res, 2008. 3. Bezemer et al. Arch Int Med, 2009. 4. Zoller et al. Circulation, 2011. 5. Couturand et al. Blood, 2014.

Baseline characteristics of CTEPH cohort CTEPH cohort (n=56) Mean age at diagnosis with CTEPH (years SD) 59.4 14.3 Prior history of acute VTE (%) 80.4% Status post PTE surgery (%) 64.3% Mean WHO functional class at diagnosis ( SD) 2.5 0.6 Mean 6WD at diagnosis (meters SD) 374.2 154.4 Hemodynamics at diagnosis: - mean mpap (mmhg SD) - mean PAOP (mmhg SD) - mean CO (L/min SD) - mean PVR (Wood units SD) 44.6 11.9 12.0 6.4 4.6 1.2 7.7 3.7

VTE history in the CTEPH and VTE cohorts CTEPH cohort (n=56) VTE cohort (n=93) Mean age at first VTE dx (years SD) 53.2 17.7 51.6 15.9 History of unprovoked VTE (%) 82.2% 80.6% Female (%) 46.4% 44.1% Caucasian (%) 92.9% 94.6% History of acute PE (%) 71.4% 65.6% History of acute proximal LE DVT (%) 53.6% 75.3% Recurrent VTE (%) 32.1% 47.3%

Frequencies of the Factor V Leiden mutation and family history of VTE CTEPH cohort (n=56) VTE cohort (n=93) p-value Factor V Leiden positive 10.7% 24.7% 0.036 First degree family member with VTE 51.8% 40.9% 0.2 2 first degree family members with VTE 28.6% 10.8% 0.006 Factor V Leiden negative AND 2 first degree family members with VTE 25.0% 5.4% 0.0005

Frequency of inherited thrombophilias in CTEPH patients with strong family histories of VTE

Frequency of inherited thrombophilias in CTEPH patients with strong family histories of VTE

Frequency of inherited thrombophilias in CTEPH patients with strong family histories of VTE Factor V Leiden: 2/16 (12.5%)

Frequency of inherited thrombophilias in CTEPH patients with strong family histories of VTE Factor V Leiden: 2/16 Prothrombin G20210A: 1/16

Frequency of inherited thrombophilias in CTEPH patients with strong family histories of VTE Factor V Leiden: 2/16 Prothrombin G20210A: 1/16

Frequency of inherited thrombophilias in CTEPH patients with strong family histories of VTE Factor V Leiden: 2/16 Prothrombin G20210A: 1/16 Protein S deficiency: 1/11

Frequency of inherited thrombophilias in CTEPH patients with strong family histories of VTE Factor V Leiden: 2/16 Prothrombin G20210A: 1/16 Protein S deficiency: 1/11 Protein C deficiency: 0/11

Frequency of inherited thrombophilias in CTEPH patients with strong family histories of VTE Factor V Leiden: 2/16 Prothrombin G20210A: 1/16 Protein S deficiency: 1/11 Protein C deficiency: 0/11 Anti-thrombin 3 deficiency: 0/11

Frequency of inherited thrombophilias in CTEPH patients with strong family histories of VTE Factor V Leiden: 2/16 Prothrombin G20210A: 1/16 Protein S deficiency: 1/11 Protein C deficiency: 0/11 Anti-thrombin 3 deficiency: 0/11 75% (12/16) of CTEPH patients with a strong family history of VTE do not carry one of the common inherited thrombophilias.

Conclusions As compared to a matched cohort with uncomplicated VTE, CTEPH patients are significantly less likely to carry the Factor V Leiden mutation significantly more likely to have a strong family history of VTE The Factor V Leiden mutation is associated with decreased risk for CTEPH. The combination of Factor V Leiden negativity and a strong family history of VTE may indicate patients at high risk for CTEPH.

Conclusions We propose that: The high frequency of unprovoked PE in CTEPH patients is due to genetic risk factors for VTE. Genetic risk factors for VTE in CTEPH patients: are distinct from common inherited thrombophilias that predispose to acute PE. may specifically predispose to chronic/nonresolving VTE events.

Familial CTEPH Pedigree 1 Pedigree 2 Pedigree 3 Key: male female deceased DVT PE DVT/PE CTEPH Familial CTEPH identified in 3/56 (5.4%) pedigrees. Desmarais and Elliott. Chest, 2016.

Acknowledgments Greg Elliott, MD Lynn Brown, MD, PhD Kirk Knowlton, MD Scott Stevens, MD Scott Woller, MD Julianna Desmarais, MD Lisa Cannon-Albright, PhD Hunter Best, PhD Kelli Sumner, BS Jadyn Sander, BS Funding source: Intermountain Research and Medical Foundation